Liver transplantation after radioembolization in a patient with unresectable HCC

Luna, Laura E. Moreno; Kwo, Paul Y.; Roberts, Lewis R.; Mettler, Teresa A.; Gansen, Denise N.; Andrews, James C.; Wiseman, Gregory A.; Misra, Vijay Laxmi

doi:10.1038/nrgastro.2009.165

Cited by 14 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For such reasons, hepatic resection after RE is very limited to anecdotal cases [5][6][7][8][9]. Recently it has been reported a case of liver metastases who underwent hepatic resection after downstaging with RE [10].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Experiences in Hepatic Surgery and Transplantation after Radioembolization

Ettorre¹,

Vennarecci²,

Santoro³

et al. 2011

J Nucl Med Radiat Ther

View full text Add to dashboard Cite

Yttrium-90 microspheres radioembolization has shown to be an effective modality of treatment in patients with primary or metastatic liver tumours [1-4]. It is usually offered to patients with advanced liver cancers. However, surgical experience after radioembolization is very limited to anecdotal cases mainly related to hepatocellular carcinoma. We have treated patients with hepatocellular carcinoma or liver metastasis mainly from colon, breast, melanoma and neuroendocrine tumours. In our experience after such treatment we were able to downstage the tumour to surgery only in the case of hepatocellular carcinoma. Five patients had liver transplantation and 1 had right hepatic resection after Yttrium-90 microspheres radioembolization. Of note 2 patients had neoplastic infiltration of a portal vein branch which resolved after treatment with Yttrium-90 microspheres radioembolization. The extra-hepatic spread was ruled out and later they were both transplanted. Here we report our initial single center experience with Yttrium-90 microspheres radioembolization as downstaging and bridging method for hepatocellular carcinoma prior liver surgery, resection or liver transplantation.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It is usually offered to patients with advanced liver cancers who are not otherwise candidates for local ablation, surgical resection, liver transplantation (LT) or have failed other previous treatment as TACE or chemotherapy. For such reasons, surgical experience after RE is very limited to anecdotal cases or small series [5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Experiences in Hepatic Surgery and Transplantation after Radioembolization

Ettorre¹,

Vennarecci²,

Santoro³

et al. 2011

J Nucl Med Radiat Ther

View full text Add to dashboard Cite

show abstract

“…The use of Y90-SIRT has led to the discovery of several novel concepts which may help patients who are undergoing potentially curative resection ( 49 50 ). One of them is the controversial downstaging as a bridge to liver resection or transplantation in selected candidates ( 16 51 52 53 54 ). Kulik et al ( 55 ) reported that following Y90-SIRT, 19 of 34 (56%) patients were successfully downstaged from UNOS T3 to T2, and of these patients, eight (23%) underwent liver transplantation.…”

Section: Y90-sirt Outcomesmentioning

confidence: 99%

Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review

et al. 2016

View full text Add to dashboard Cite

Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options. Ytrrium-90 selective internal radiation therapy (Y90-SIRT) with glass microspheres is rapidly gaining acceptance as a potential therapy for intermediate and advanced stage primary hepatocellular carcinoma and liver metastases. The technique involves delivery of Y90 infused glass microspheres via the hepatic arterial blood flow to the appropriate tumor. The liver tumor receives a highly concentrated radiation dose while sparing the healthy liver parenchyma due to its preferential blood supply from portal venous blood. There are two commercially available devices: TheraSphere® and SIR-Spheres®. Although, Y90-SIRT with glass microspheres improves median survival in patients with intermediate and advanced hepatocellular carcinoma and has the potential to downstage hepatocellular carcinoma so that the selected candidates meet the transplantable criteria, it has not gained widespread acceptance due to the lack of large randomized controlled trials. Currently, there are various clinical trials investigating the use of Y90-SIRT with glass microspheres for treatment of hepatocellular carcinoma and the outcomes of these trials may result in the incorporation of Y90-SIRT with glass microspheres into the treatment guidelines as a standard therapy option for patients with intermediate and advanced stage hepatocellular carcinoma.

show abstract

“…[1,2] In ltration into adjacent tissues and metastasis to distant organs are the causes of death in the majority of HCC patients. [3,4] Thus far, the detailed molecular mechanisms underlying the initiation and progression of tumor metastasis remain far from fully understood. As a result, medical prevention and treatment of HCC is disappointing.…”

Section: Introductionmentioning

confidence: 99%

C1orf61 promotes hepatocellular carcinoma metastasis and affects the therapeutic response to sorafenib

Wang

Huang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background C1orf61 is a specific transcriptional activator that is highly up-regulated during weeks 4–9 of human embryogenesis, the period in which most organs develop. We have previously demonstrated that C1orf61 acts as a tumor activator in human hepatocellular carcinoma (HCC) tumorigenesis and metastasis. However, the underlying molecular mechanisms of tumor initiation and progression in HCC remain obscure. Methods In this study, we demonstrated that the pattern of C1orf61 expression was closely correlated with metastasis in liver cancer cells. Gene expression profiling analysis indicated that C1orf61 regulated diverse genes related to cell growth, migration, invasion and epithelial-mesenchymal transition (EMT). Results Results showed that C1orf61 promotes hepatocellular carcinoma metastasis by inducing cellular EMT in vivo and in vitro. Moreover, C1orf61-induced cellular EMT and migration are involved in the activation of the STAT3 and Akt cascade pathways. We also found that C1orf61 was associated with HBV infection-induced cell migration in HCC. In addition, C1orf61 expression improved the efficacy of the anticancer therapy sorafenib in HCC patients. For the first time, we report a regulatory pathway by which C1orf61 promoted cancer cell metastasis and regulated the therapeutic response to sorafenib. Conclusions These findings increased our understanding of the molecular events that regulate metastasis and treatment in HCC.

show abstract

Liver transplantation after radioembolization in a patient with unresectable HCC

Cited by 14 publications

References 19 publications

Experiences in Hepatic Surgery and Transplantation after Radioembolization

Experiences in Hepatic Surgery and Transplantation after Radioembolization

Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review

C1orf61 promotes hepatocellular carcinoma metastasis and affects the therapeutic response to sorafenib

Contact Info

Product

Resources

About